Formerly developed thermal imaging technology for medical applications. Aimed to provide diagnostic screening for early breast cancer detection. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Our checks did not surface a specific strength to highlight here.
A loss of $3.1M against $0 in annual sales.
The stock sits at $0.0000. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.